Minimal Residual Disease Eradication by Azacitidine Maintenance in a Patient with Core-Binding Factor Acute Myeloid...

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Core-binding factor acute myeloid leukemia (CBF-AML) typically has a favorable prognosis, but up to 35% of patients experience disease relapse.
• Minimal residual disease (MRD) monitoring, particularly via sensitive real-time quantitative PCR, is vital for identifying high-risk patients.
• The optimal management strategy for CBF-AML patients in complete remission but with detectable MRD post-treatment remains uncertain.

Observation:

• This report details a case of CBF-AML where minimal residual disease (MRD) persisted after standard induction and consolidation therapies.
• The patient was positive for MRD despite achieving complete morphologic remission.

Findings:

• Azacitidine maintenance therapy was administered to the MRD-positive CBF-AML patient.
• This maintenance therapy successfully eradicated minimal residual disease (MRD) in the patient.

Implications:

• The findings suggest that azacitidine maintenance therapy could be a viable strategy for eradicating MRD in CBF-AML.
• This approach may offer an alternative to more aggressive preemptive interventions like stem cell transplantation or intensive chemotherapy.
• Further research into hypomethylating agents for maintenance therapy in CBF-AML is warranted to validate these findings.